BECATTINI v. LUTRONIC CORPORATION

CourtDistrict Court, E.D. Pennsylvania
DecidedDecember 8, 2021
Docket2:19-cv-02464
StatusUnknown

This text of BECATTINI v. LUTRONIC CORPORATION (BECATTINI v. LUTRONIC CORPORATION) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
BECATTINI v. LUTRONIC CORPORATION, (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

DAVID BECATTINI, CIVIL ACTION

Plaintiff, NO. 19-2464-KSM v.

LUTRONIC CORPORATION, et al.

Defendants.

MEMORANDUM

MARSTON, J. December 8, 2021

Plaintiff David Becattini has sued his former employer, Lutronic Corporation, and his former boss, Jeffery Knight (together, “Defendants”), alleging that Defendants violated his rights under the Family and Medical Leave Act (“FMLA”) by denying his request for time off to care for his sick mother and terminating him for making the request. (Doc. No. 1.) Becattini brings claims for interference and retaliation under the FMLA. (Id. at 7–9.) He also brings a claim under Pennsylvania’s Wage Payment and Collection Law (“WPCL”) for Defendants’ alleged failure to pay him commissions he was owed following his termination. (Id. at 9.) Defendants have filed a motion for summary judgment, arguing that Becattini’s FMLA claims must fail because he was not FMLA eligible when he requested time off given that Lutronic had fewer than fifty employees and, even if he were eligible, Lutronic terminated his employment for legitimate, non-retaliatory reasons. (Doc. Nos. 39, 41.) Defendants also argue that the WPCL claim fails because Becattini has failed to establish that he was owed any commissions that Lutronic did not pay. (Id.) Becattini opposes the motion. (Doc. No. 50.) For the reasons below, Defendants’ motion is granted. I. Factual Background Viewing the evidence in the light most favorable to Becattini, the relevant facts are as follows. A. Lutronic’s Presence in the United States Lutronic is a South Korea-based medical device sales company with an office in

Billerica, Massachusetts. (Doc. No. 50-1, Ex. 7 at 104, 107.) In late 2018, Lutronic had three regional sales managers, including Becattini, who supervised teams of sales representatives. (Doc. No. 50-1, Ex. 11 at 162.) Lutronic also had a team of approximately twelve “independent sales representatives” who were paid with checks and received IRS Forms 1099. (Doc. No. 50- 1, Ex. 1 at 111:13–112:24.) Some of the independent sales representatives only sold products for Lutronic, but some sold products for other companies as well. (Id. at 112:11–17.) The independent sales representatives were only paid commissions—they did not receive a salary. (Id. at 116:6–22.) In addition to its sales force, Lutronic also had a team of “clinical trainers,” nurses who were paid a daily rate to train customers on Lutronic’s devices. (Id. at 113:24–114:16.) As with

the independent sales representatives, clinical trainers were paid with checks and received IRS Forms 1099. (Id. at 114:17–22.) B. Becattini’s Role at Lutronic In January 2017, Becattini was hired to serve as Lutronic’s East Regional Sales Manager. (Doc. No. 39-2, Ex. C at 117.) He was paid a base salary and earned a 2.5% commission on sales in his region. (Id.) Becattini reported to Lutronic’s Vice President of Sales1 and supervised “between six and eight” sales representatives. (Doc. No. 39-2, Ex. A at 78:14–24.) In this role, he was responsible for hiring, training, and developing sales representatives, promoting Lutronic’s products, and preparing sales forecasts and plans for customer retention. (Id. at 78:2.) Becattini’s performance was initially measured based on the “total sales” made in his region

(Doc. No. 50-1, Ex. 1 at 98:6), but when Knight took over as Vice President of Sales, he implemented a quota system, requiring each region to make a certain amount per year in sales (id. at 99:3–7). C. Becattini’s Job Performance Becattini says that he never received any written or verbal performance reviews from Knight, but they did have “some discussions” about his performance. (Id. at 105:21–106:15.) In June 2018, Knight emailed Becattini requesting “a list of deals that your reps are working [on] and their updates, and which deals you expect to close.” (Doc. No. 39-2, Ex. D at 123.) Knight explained, “I looked at the closed deals for June and nothing is happening with your reps and only one week left. . . . You were only tasked with working with your reps this month to close deals in the field. Send updates today.” (Id.) Becattini responded, “Feeling a bit under

appreciated right now. Updated forecast attached.” (Id.) At his deposition, Becattini testified that he felt “under appreciated” because Knight was new to his position and did not recognize all of the sales in the pipeline. (Doc. No. 50-1, Ex. 1 at 122:6–123:6.) In July 2018, Knight told Becattini that he needed to focus on filling sales representative positions in New York and Philadelphia. (Doc. No. 39-2, Ex. E at 125.) Becattini did not fill the

1 At the beginning of his tenure, Becattini reported to Jim Spivey, Lutronic’s then-Vice President of Sales. (Doc. No. 50-1, Ex. 1 at 96:10–21.) Following Spivey’s departure, Becattini began reporting to Knight, who replaced Spivey as Vice President of Sales. (Id.) positions, but he believes he was unable to do so because the compensation package Knight authorized him to offer was below the market rate. (Doc. No. 39-2, Ex. A at 137:6–9.) Knight also implemented a quota system for regional sales managers and sales representatives in 2018. (Doc. No. 50-1, Ex. 1 at 99:1–7.) Becattini’s quota for 2018 was about $9.5 million, and his region only made about $3.8 million in sales. (Id. at 100:3–23.) But

Becattini was not alone—none of the regional managers met their quotas in 2018. (Id. at 100:14.) Knight had formulated the quotas on an assumption that a new Lutronic device would be approved by the FDA and boost sales, but the FDA never granted approval of that device, so the accompanying increase in sales was not realized. (Id. at 102:13–23.) Although he fell short of his quota, Becattini’s region was “the number one region in the country.” (Id. at 101:2–3.) D. Becattini’s Request for Time Off In November 2018, Becattini informed Knight that his mother had been diagnosed with late-stage lung cancer and he would “need time off” to care for her because his father was elderly and unable to do so. (Id. at 151:15–152:6.) Knight refused his request and told Becattini that he needed to be “in the field” closing sales through the end of the year. (Id. at 153:16.) Later that month, Becattini told Knight again that he needed to be with his mother, but Knight told him that

he would be terminated if he did not stay in the field through the end of the year. (Id. at 154:12– 155:5.) Becattini stayed in the field through the end of 2018. (Id. at 160:18–161:1.) E. Becattini’s Termination On January 3, 2019, Knight called to inform Becattini that he was being terminated effective January 15, 2019. (Id. at 162:4–15.) Knight offered several explanations for the termination: Becattini’s poor performance,2 alleged issues between Becattini and a female subordinate, and that Becattini was interviewing for other jobs. (Id. at 163:11–24.) After Becattini’s termination was effective, Lutronic’s Chief Financial Officer sent Becattini a letter with his final commission check. (Doc. No. 39-2, Ex. I.) The letter explained that the check included “commissions earned on sales for which payment in full has been

received by the customer.” (Id. at 143.) Becattini was not paid commission on a “big deal” with a day spa client (id. at 148:2–6), but he did not earn that commission because the deal with the day spa never closed and the day spa never paid Lutronic (id. at 148:19–149:4; Doc. No. 39-2, Ex. J ¶ 8). Under Lutronic’s commission policy, if a customer “returned the equipment and never paid anything, . . . [regional managers] would not be entitled” to commissions. (Doc. No. 50-1, Ex. 1 at 16:17–24.) II. Procedural History On June 6, 2019, Becattini commenced this action, asserting claims for interference and retaliation under the FMLA and a claim under the Pennsylvania’s WPCL.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
United States v. Robert Asmar and Kathleen Asmar
827 F.2d 907 (Third Circuit, 1987)
Leese v. Adelphoi Village, Inc.
516 F. App'x 192 (Third Circuit, 2013)
Ronald Ross v. Kevin Gilhuly
755 F.3d 185 (Third Circuit, 2014)
Budhun v. Reading Hospital & Medical Center
765 F.3d 245 (Third Circuit, 2014)
De Asencio v. Tyson Foods, Inc.
342 F.3d 301 (Third Circuit, 2003)
Renart v. Chartwells
122 F. App'x 559 (Third Circuit, 2004)
Brian Palan v. Inovio Pharmaceuticals Inc
653 F. App'x 97 (Third Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
BECATTINI v. LUTRONIC CORPORATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/becattini-v-lutronic-corporation-paed-2021.